AMV-564
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | AMV-564 |
| Trade Name | |
| Synonyms | AMV564|AMV 564|T652 |
| Drug Descriptions |
AMV-564 is a tandem diabody that targets both CD33 and CD3, which may result in increased T-cell activation and death of CD33-expressing tumor cells (PMID: 27189165, PMID: 28157217). |
| DrugClasses | CD3 Antibody 119 CD33 Antibody 17 |
| CAS Registry Number | 2243775-32-6 |
| NCIT ID | C135632 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| AMV-564 | AMV-564 | 0 | 3 |
| AMV-564 + Pembrolizumab | AMV-564 Pembrolizumab | 0 | 0 |
CKB BOOST